Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1993 Jun;91(6):2873–2879. doi: 10.1172/JCI116532

Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor.

K A Hajjar 1
PMCID: PMC443357  PMID: 8390492

Abstract

Endothelial cells impart thromboresistance to the blood vessel wall. As modulators of fibrinolytic activity, these cells synthesize and secrete tissue plasminogen activator (t-PA) as well as its physiologic inhibitor, plasminogen activator inhibitor-1. In addition, endothelial cells support membrane-associated assembly of plasminogen and tissue plasminogen activator. Recently, an M(r) approximately 40,000 protein expressed on endothelial cells has been shown to interact noncompetitively through disparate mechanisms with both t-PA and plasminogen, suggesting trimolecular assembly of enzyme, substrate, and receptor (Hajjar, K. A. 1991. J. Biol. Chem. 266:21962-21970). In the present study, treatment of cultured endothelial cells with DL-homocysteine was specifically associated with a selective reduction in cellular binding sites for t-PA. This 65% decrease in binding was associated with a 60% decrease in cell-associated t-PA activity. No change in affinity for t-PA or plasminogen or in the maximal number of binding sites for plasminogen was observed. Matrix-associated t-PA binding sites were not affected. These data suggest a new mechanism whereby homocysteine may perturb endothelial cell function, thus promoting a prothrombotic state at the surface of the blood vessel wall.

Full text

PDF
2873

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnathan E. S., Kuo A., Van der Keyl H., McCrae K. R., Larsen G. R., Cines D. B. Tissue-type plasminogen activator binding to human endothelial cells. Evidence for two distinct binding sites. J Biol Chem. 1988 Jun 5;263(16):7792–7799. [PubMed] [Google Scholar]
  2. Boers G. H., Smals A. G., Trijbels F. J., Fowler B., Bakkeren J. A., Schoonderwaldt H. C., Kleijer W. J., Kloppenborg P. W. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985 Sep 19;313(12):709–715. doi: 10.1056/NEJM198509193131201. [DOI] [PubMed] [Google Scholar]
  3. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991 Apr 25;324(17):1149–1155. doi: 10.1056/NEJM199104253241701. [DOI] [PubMed] [Google Scholar]
  4. Eaton D. L., Fless G. M., Kohr W. J., McLean J. W., Xu Q. T., Miller C. G., Lawn R. M., Scanu A. M. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci U S A. 1987 May;84(10):3224–3228. doi: 10.1073/pnas.84.10.3224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ewadh M. J., Tudball N., Rose F. A. Homocysteine uptake by human umbilical vein endothelial cells in culture. Biochim Biophys Acta. 1990 Sep 24;1054(3):263–266. doi: 10.1016/0167-4889(90)90097-w. [DOI] [PubMed] [Google Scholar]
  6. Genest J. J., Jr, McNamara J. R., Salem D. N., Wilson P. W., Schaefer E. J., Malinow M. R. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol. 1990 Nov;16(5):1114–1119. doi: 10.1016/0735-1097(90)90542-w. [DOI] [PubMed] [Google Scholar]
  7. Gonzalez-Gronow M., Edelberg J. M., Pizzo S. V. Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site. Biochemistry. 1989 Mar 21;28(6):2374–2377. doi: 10.1021/bi00432a005. [DOI] [PubMed] [Google Scholar]
  8. Hajjar K. A., Gavish D., Breslow J. L., Nachman R. L. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989 May 25;339(6222):303–305. doi: 10.1038/339303a0. [DOI] [PubMed] [Google Scholar]
  9. Hajjar K. A., Hamel N. M., Harpel P. C., Nachman R. L. Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest. 1987 Dec;80(6):1712–1719. doi: 10.1172/JCI113262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hajjar K. A., Hamel N. M. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J Biol Chem. 1990 Feb 15;265(5):2908–2916. [PubMed] [Google Scholar]
  11. Hajjar K. A., Harpel P. C., Jaffe E. A., Nachman R. L. Binding of plasminogen to cultured human endothelial cells. J Biol Chem. 1986 Sep 5;261(25):11656–11662. [PubMed] [Google Scholar]
  12. Hajjar K. A., Nachman R. L. Endothelial cell-mediated conversion of Glu-plasminogen to Lys-plasminogen. Further evidence for assembly of the fibrinolytic system on the endothelial cell surface. J Clin Invest. 1988 Nov;82(5):1769–1778. doi: 10.1172/JCI113790. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hajjar K. A. The endothelial cell tissue plasminogen activator receptor. Specific interaction with plasminogen. J Biol Chem. 1991 Nov 15;266(32):21962–21970. [PubMed] [Google Scholar]
  14. Harker L. A., Slichter S. J., Scott C. R., Ross R. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med. 1974 Sep 12;291(11):537–543. doi: 10.1056/NEJM197409122911101. [DOI] [PubMed] [Google Scholar]
  15. Hayashi T., Honda G., Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood. 1992 Jun 1;79(11):2930–2936. [PubMed] [Google Scholar]
  16. Hill-Zobel R. L., Pyeritz R. E., Scheffel U., Malpica O., Engin S., Camargo E. E., Abbott M., Guilarte T. R., Hill J., McIntyre P. A. Kinetics and distribution of 111Indium-labeled platelets in patients with homocystinuria. N Engl J Med. 1982 Sep 23;307(13):781–786. doi: 10.1056/NEJM198209233071303. [DOI] [PubMed] [Google Scholar]
  17. Lentz S. R., Sadler J. E. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest. 1991 Dec;88(6):1906–1914. doi: 10.1172/JCI115514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Loskutoff D. J., Sawdey M., Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb. 1989;9:87–115. [PubMed] [Google Scholar]
  19. Malinow M. R., Kang S. S., Taylor L. M., Wong P. W., Coull B., Inahara T., Mukerjee D., Sexton G., Upson B. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation. 1989 Jun;79(6):1180–1188. doi: 10.1161/01.cir.79.6.1180. [DOI] [PubMed] [Google Scholar]
  20. Markus G., Evers J. L., Hobika G. H. Comparison of some properties of native (Glu) and modified (Lys) human plasminogen. J Biol Chem. 1978 Feb 10;253(3):733–739. [PubMed] [Google Scholar]
  21. McLean J. W., Tomlinson J. E., Kuang W. J., Eaton D. L., Chen E. Y., Fless G. M., Scanu A. M., Lawn R. M. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987 Nov 12;330(6144):132–137. doi: 10.1038/330132a0. [DOI] [PubMed] [Google Scholar]
  22. Miles L. A., Fless G. M., Levin E. G., Scanu A. M., Plow E. F. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989 May 25;339(6222):301–303. doi: 10.1038/339301a0. [DOI] [PubMed] [Google Scholar]
  23. Morjana N. A., Gilbert H. F. Effect of protein and peptide inhibitors on the activity of protein disulfide isomerase. Biochemistry. 1991 May 21;30(20):4985–4990. doi: 10.1021/bi00234a021. [DOI] [PubMed] [Google Scholar]
  24. Mudd S. H., Skovby F., Levy H. L., Pettigrew K. D., Wilcken B., Pyeritz R. E., Andria G., Boers G. H., Bromberg I. L., Cerone R. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985 Jan;37(1):1–31. [PMC free article] [PubMed] [Google Scholar]
  25. Munson P. J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  26. Noiva R., Lennarz W. J. Protein disulfide isomerase. A multifunctional protein resident in the lumen of the endoplasmic reticulum. J Biol Chem. 1992 Feb 25;267(6):3553–3556. [PubMed] [Google Scholar]
  27. Rodgers G. M., Conn M. T. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 1990 Feb 15;75(4):895–901. [PubMed] [Google Scholar]
  28. Rodgers G. M., Kane W. H. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest. 1986 Jun;77(6):1909–1916. doi: 10.1172/JCI112519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Schleef R. R., Podor T. J., Dunne E., Mimuro J., Loskutoff D. J. The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator. J Cell Biol. 1990 Jan;110(1):155–163. doi: 10.1083/jcb.110.1.155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Sprengers E. D., Kluft C. Plasminogen activator inhibitors. Blood. 1987 Feb;69(2):381–387. [PubMed] [Google Scholar]
  31. Starkebaum G., Harlan J. M. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest. 1986 Apr;77(4):1370–1376. doi: 10.1172/JCI112442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Uhlemann E. R., TenPas J. H., Lucky A. W., Schulman J. D., Mudd S. H., Shulman N. R. Platelet survival and morphology in homocystinuria due to cystathionine synthase deficiency. N Engl J Med. 1976 Dec 2;295(23):1283–1286. doi: 10.1056/NEJM197612022952303. [DOI] [PubMed] [Google Scholar]
  33. de Groot P. G., Willems C., Boers G. H., Gonsalves M. D., van Aken W. G., van Mourik J. A. Endothelial cell dysfunction in homocystinuria. Eur J Clin Invest. 1983 Oct;13(5):405–410. doi: 10.1111/j.1365-2362.1983.tb00121.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES